KR950026524A - 피부질환 치료용 의약조성물 - Google Patents

피부질환 치료용 의약조성물 Download PDF

Info

Publication number
KR950026524A
KR950026524A KR1019950003640A KR19950003640A KR950026524A KR 950026524 A KR950026524 A KR 950026524A KR 1019950003640 A KR1019950003640 A KR 1019950003640A KR 19950003640 A KR19950003640 A KR 19950003640A KR 950026524 A KR950026524 A KR 950026524A
Authority
KR
South Korea
Prior art keywords
pharmaceutical composition
sulfate
weight
total
composition according
Prior art date
Application number
KR1019950003640A
Other languages
English (en)
Other versions
KR0163563B1 (ko
Inventor
정계종
장만식
전종옥
전재광
최완수
김성철
Original Assignee
김종인
영진약품공업 주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 김종인, 영진약품공업 주식회사 filed Critical 김종인
Priority to KR1019950003640A priority Critical patent/KR0163563B1/ko
Publication of KR950026524A publication Critical patent/KR950026524A/ko
Application granted granted Critical
Publication of KR0163563B1 publication Critical patent/KR0163563B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

본 발명은 피부질환 치료에 유용한 의약조성물에 관한 것으로서, 더욱 상세하게는 피부재생 촉진작용을 나타내는 송아지의 제단백 혈액주출물과 세균성 감염을 억제하는 아미노글리코사이드계 항생제를 유효성분으로 함유하므로써 화상, 외상, 일반수술창, 동창, 욕창, 모낭염, 농가진, 간찰진, 방사성궤양, 심상성좌창, 감염성 습진양 피부염 등의 치료에 유용한 피부질환 치료용 의약조성물에 관한 것이다.

Description

피부질환 치료용 의약조성물
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (8)

  1. 송아지의 제단백 혈액추출물과 아미노글리코사이드계 항생제를 유효성분으로 함유하는 피부질환 치료용의 약조성물.
  2. 제1항에 있어서, 상기 송아지외 제단백 혈액추출물은 전체 의약조성에 대하여 5∼20중량%로 함유되어 있는 것을 특징으로 하는 의약조성물.
  3. 제1항에 있어서, 상기 아미노글리코사이드계 항생제는 전체 의약조성에 대하여 0.3∼1중량%로 함유되어 있는 것을 특징으로 하는 의약조성물.
  4. 제1항 또는 제3항에 있어서, 상기 아미노글리코사이드계 항생제는 황산네오마이신, 황산겐타마이신, 황산미크로노마이신, 황산아미카신, 황산가나마이신, 황산토브라마이신, 황산네틸마이신, 황산디베카신, 황산시소마이신 및 황산아스트로마이신 중에서 선택된 것임을 특징으로 하는 의약조성물.
  5. 제4항에 있어서, 상기 아미노글리코사이드계 항생제는 황산미크로노마이신임을 특징으로 하는 의약조성물.
  6. 제1항에 있어서, 상기 의약조성물은 전체조성에 대해 담체로서 폴록사머 18∼22중량%, 프로필렌 1∼5중량% 및 염화나트륨 0.5∼3중량%를 함유하는 겔제임을 특징으로 하는 의약조성물.
  7. 제1항에 있어서, 상기 의약조성물은 전체 조성에 대해 담체로서 플록사머 18∼22중량%, 프로필렌글리콜 1∼5중량% 및 루비톨 EHO 5∼15중량%를 함유하는 겔크림제임을 특징으로 하는 의약조성물.
  8. 제1항에 있어서, 상기 의약조성물은 전체조성에 대해 담체로서 폴록사머 5∼15중량%와 프로필렌글리콜 1∼5중량%를 함유하는 외용액제임을 특징으로 하는 의약조성물.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019950003640A 1994-03-23 1995-02-24 피부질환 치료용 의약조성물 KR0163563B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1019950003640A KR0163563B1 (ko) 1994-03-23 1995-02-24 피부질환 치료용 의약조성물

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR19940005839 1994-03-23
KR94-5839 1994-03-23
KR1019950003640A KR0163563B1 (ko) 1994-03-23 1995-02-24 피부질환 치료용 의약조성물

Publications (2)

Publication Number Publication Date
KR950026524A true KR950026524A (ko) 1995-10-16
KR0163563B1 KR0163563B1 (ko) 1998-12-01

Family

ID=19379444

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019950003640A KR0163563B1 (ko) 1994-03-23 1995-02-24 피부질환 치료용 의약조성물

Country Status (6)

Country Link
US (1) US5731007A (ko)
EP (1) EP0751776A1 (ko)
JP (1) JP2804846B2 (ko)
KR (1) KR0163563B1 (ko)
CN (1) CN1143324A (ko)
WO (1) WO1995025523A1 (ko)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7138133B2 (en) 2001-10-10 2006-11-21 The Procter & Gamble Company Orally administered liquid compositions
US20070003552A1 (en) * 2002-07-09 2007-01-04 Gebbink Martijn F B Cross-beta structure comprising amyloid binding proteins and methods for detection of the cross-beta structure, for modulating cross-beta structures fibril formation and for modulating cross-beta structure-mediated toxicity and method for interfering with blood coagulation
EP1380290A1 (en) * 2002-07-09 2004-01-14 Universitair Medisch Centrum Utrecht Cross-beta structure pathway and its therapeutic relevance
DE10241074A1 (de) * 2002-09-05 2004-03-11 Beiersdorf Ag Emulsionen mit Mikrocellulose
US20090202980A1 (en) * 2005-03-21 2009-08-13 Crossbeta Biosciences B.V. Cross-Beta Structure Comprising Amyloid Binding Proteins and Methods for Detection of the Cross-Beta Structure, for Modulating Cross-Beta Structures Fibril Formation and for Modulating Cross-Beta Structure-Mediated Toxicity and Method for Interfering With Blood Coagulation
CN100360141C (zh) * 2005-07-12 2008-01-09 锦州奥鸿药业有限责任公司 小牛血清去蛋白凝胶和小牛血清去蛋白眼用凝胶
CA2615078A1 (en) * 2005-07-13 2007-01-18 Crossbeta Biosciences B.V. Methods for determining the effect of a treatment on the cross-.beta. structure content of a protein; selection of treatments and uses thereof
US8114832B2 (en) * 2005-07-13 2012-02-14 Crossbeta Biosciences B.V. Method for detecting and/or removing a protein comprising a cross-beta structure from a pharmaceutical composition
EP1910844B1 (en) * 2005-07-13 2012-04-18 Crossbeta Biosciences B.V. Cross-beta structure binding compounds
CA2645930A1 (en) * 2006-03-17 2007-09-27 Crossbeta Biosciences B.V. Methods of binding of cross-beta structures by chaperones
CN101230090B (zh) * 2007-01-24 2011-11-02 中国生化制药工业协会 血肽x及其衍生物h及其制备方法和用途
EP2016935A1 (en) * 2007-07-09 2009-01-21 Intendis GmbH Pharmaceutical composition for topical application of poorly soluble compounds
EP2058001A1 (en) * 2007-11-08 2009-05-13 Crossbeta Biosciences B.V. Enhancement of immunogenicity of antigens
EP2058000A1 (en) * 2007-11-08 2009-05-13 Crossbeta Biosciences B.V. Immunogenic compositions capable of activating T cells
KR101724599B1 (ko) * 2015-03-11 2017-04-10 연세대학교 산학협력단 점액 발현을 촉진하기 위한 조성물

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT200257B (ko) * 1955-12-13 1958-10-25 Salco Basel A. G.
US3293836A (en) * 1964-07-29 1966-12-27 Jacobsen Mfg Co Air-supported lawn mower
GB1390541A (en) * 1971-04-14 1975-04-16 Otsuka Kagaku Yakuhin Anti-inflammatory compositions
DE2700043C2 (de) * 1977-01-03 1983-12-08 Thera Gesellschaft für Patentverwertung mbH, 8036 Herrsching Mittel zur Verbesserung der Durchblutung und Wundheilung
US5290555A (en) * 1989-09-14 1994-03-01 Revlon Consumer Products Corporation Cosmetic compositions with structural color
IT1249711B (it) * 1991-09-30 1995-03-09 Boniscontro E Gazzone S R L Composizioni farmaceutiche, per uso topico, contenenti "scavengers" di radicali liberi dell'ossigeno e antibatterici,indicate nella terapia dei tessuti superficiali.

Also Published As

Publication number Publication date
JPH09503526A (ja) 1997-04-08
US5731007A (en) 1998-03-24
KR0163563B1 (ko) 1998-12-01
WO1995025523A1 (en) 1995-09-28
JP2804846B2 (ja) 1998-09-30
EP0751776A1 (en) 1997-01-08
CN1143324A (zh) 1997-02-19

Similar Documents

Publication Publication Date Title
KR950026524A (ko) 피부질환 치료용 의약조성물
PT806941E (pt) Composicoes anti-bacterianas liposomicas de rigidez baixa
GEP20053429B (en) 3-Aminoquinazolin-2,4-Dione, Pharmaceutical Composition Containing Them and Use Thereof as Antibacterial Agents
GEP19991538B (en) Derivatives of Erytromycin and Pharmaceutical Composition on their Basis
BRPI0112962B8 (pt) composições farmacêuticas compreendendo ácido hialurônico, ácido glicirretínico e polivinilpirrolidona, e uso desses compostos na preparação de medicamentos
BR9611400A (pt) "agentes antimicobiano de benzoxazina".
EP1013283A3 (en) Pharmaceutical and foodstuff compositions containing transferrins and antibacteral agents for potentiating host defence activity and the treatment of infections
DE60018409D1 (de) Verwendung von antiseptika zur herstelllung von arzneimitteln zur prophylaxe und behandlung von infektionen und/ oder funktionellen gewebeumformungen im körperinneren
NZ510153A (en) Tan-1057 derivatives with reduced toxicity and their use in medicaments for treating bacterial infections in humans and mammals
Waterman et al. The effect of a prophylactic topical antibiotic (cephalothin) on the incidence of wound infection
BR0006301A (pt) Macrólidos antibacterianos e pró-cinéticos
GEP20032970B (en) Pharmaceutical Compositions of Tizoxanide and Nitazoxanide
BR0100228A (pt) Macrolìdeos com 13 e 14 elementos antibacterianos e procinéticos e seus intermediários
JPS57143000A (en) Antibiotic compound, manufacture and medical use
BR9807444A (pt) Produto antimicrobial
DE3869010D1 (de) Miocamycin enthaltende pharmazeutische zusammensetzungen fuer die topische anwendung.
JP2002302404A (ja) 抗菌防黴助剤
ME00858B (me) UPOTREBA 8a-AZALIDA U VETERINI KAO ANTIMIKROBNA SREDSTVA
KR900013971A (ko) 질 감염 치료용 푸르푸로마이신 및 그의 투여 제형
AR045070A1 (es) Preparados farmaceuticos topicos de acido ascorbico con efecto post-antimicotico
Nasir et al. Human amniotic membrane as a versatile biological dressing: a preliminary report
ATE163294T1 (de) Die antibiotika ge 37468 a, b und c
ES442505A1 (es) Procedimiento de preparacion de la 4-0-n2',6'-diamino-2',3',6' - tridesoxi-alfa, d-ribohexopiranosiln6-0 - n3" - metila-mino-3",4",6"tridesoxi alfa,d-xilohexopiranosiln2-desoxies- treptamina.
US3026247A (en) Pharmaceutical preparation
JPS57142999A (en) Antibiotic compound, manufacture and medical use

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
LAPS Lapse due to unpaid annual fee